Nanoliposomal irinotecan in metastatic pancreatic cancer - Authors' reply

Lancet. 2016 May 14;387(10032):1997. doi: 10.1016/S0140-6736(16)30365-8.

Authors

Li-Tzong Chen¹, Andrea Wang-Gillam², Daniel D Von Hoff³, Eliel Bayever⁴, Bruce Belanger⁴

Affiliations

¹ National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan; Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan. Electronic address: leochen@nhri.org.tw.
² Washington University School of Medicine, St Louis, MO, USA.
³ TGen, Phoenix, AZ, USA; HonorHealth, Scottsdale, AZ, USA.
⁴ Merrimack Pharmaceuticals, Inc, Cambridge, MA, USA.

PMID: 27203770
DOI: 10.1016/S0140-6736(16)30365-8

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Pancreatic Ductal / drug therapy*
Female
Humans
Male
Pancreatic Neoplasms / drug therapy*